Pediatric Drugs

, Volume 14, Issue 6, pp 417–427 | Cite as

Paliperidone Extended Release

In Adolescents with Schizophrenia
  • Caroline M. Perry
Adis Drug Profile


Paliperidone, the major active metabolite of risperidone, is an atypical antipsychotic agent formulated as an extended-release (ER) tablet suitable for once-daily oral administration. Paliperidone ER is approved for the treatment of adolescents aged 12–17 years with schizophrenia in the US (the focus of this review). It is also approved for the treatment of adults with schizophrenia or schizoaffective disorder.

Paliperidone ER has shown efficacy in the treatment of patients aged 12–17 years with acutely symptomatic schizophrenia in a randomized, double-blind, parallel-group, placebo-controlled, multicenter, 6-week trial. The primary endpoint was the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score to day 43 or the final assessment point post-baseline.

Patients with a PANSS total score of 60–120 received one of three weight-based, fixed once-daily doses of paliperidone ER (patients weighing 29 kg to <51 kg: 1.5mg [low-dose], 3mg [medium], or 6mg [high]; patients weighing >51 kg: 1.5mg [low], 6mg [medium], or 12mg [high]), or placebo.

Compared with placebo, significant improvements in mean PANSS total scores were reported for the medium-dose (3–6mg) paliperidone ER treatment groups. There were no significant differences in mean PANSS total scores between the recipients of low-dose or high-dose paliperidone ER versus placebo. Mean PANSS total scores in the actual dose treatment groups (regardless of weight) decreased from baseline (i.e. improved) and were significantly lower for the 3, 6, and 12mg groups than for the placebo group.

Treatment-emergent adverse events were dose related in adolescents with schizophrenia who received weight-based fixed doses of paliperidone ER.


Schizophrenia Paliperidone Early Onset Schizophrenia Paliperidone Extended Release Plasma Paliperidone Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Acknowledgments and Disclosures

The manuscript was reviewed by: M.D. Jibson, Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA; A.S. Robb, Department of Psychiatry and Behavioral Sciences and Pediatrics, Children’s National Medical Center, Washington, DC, USA.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offerred an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.


  1. 1.
    Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs 2011 Jan 22; 71 (2): 179–208PubMedCrossRefGoogle Scholar
  2. 2.
    Gentile S. Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. Paediatr Drugs 2011 Oct 1; 13 (5): 291–302PubMedCrossRefGoogle Scholar
  3. 3.
    Pandina G, Petersen T, Singh J, et al. Cognitive functioning in adolescents with schizsophrenia treated with paliperidone: interim data from a 6-month, open-label study [poster no. 34]. 58th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2011 Oct 18–23; Toronto (ON)Google Scholar
  4. 4.
    Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011 Dec 15; 70 (12): 1179–87PubMedCrossRefGoogle Scholar
  5. 5.
    Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006; 20 (10): 841–66PubMedCrossRefGoogle Scholar
  6. 6.
    Janssen Pharmaceuticals, Inc. Invega® (paliperidone) extended-release tablets: US prescribing information [online]. Available from URL: [Accessed 2012 Oct 2]
  7. 7.
    Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006 Oct; 22 (10): 1879–92PubMedCrossRefGoogle Scholar
  8. 8.
    Yang LPH, Plosker GL. Paliperidone extended release. CNS Drugs 2007; 21 (5): 417–25; discussion 26–7PubMedCrossRefGoogle Scholar
  9. 9.
    Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010 Jul 9; 70 (10): 1295–317PubMedCrossRefGoogle Scholar
  10. 10.
    Yang LPH. Oral paliperidone: a review of its use in the management of schizoaffective disorder. CNS Drugs 2011; 25 (6): 525–38CrossRefGoogle Scholar
  11. 11.
    Schwartzer JJ, Morrison RL, Ricci LA, et al. Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model ofescalated aggression. Psychopharmacology (Berl) 2009 May; 203 (4): 653–63CrossRefGoogle Scholar
  12. 12.
    Corena-McLeod M del P, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res 2008 Oct 3; 1233: 8–19CrossRefGoogle Scholar
  13. 13.
    Muly EC, Votaw JR, Ritchie J, et al. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 2012 Apr; 341 (1): 81–9PubMedCrossRefGoogle Scholar
  14. 14.
    Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008 Apr; 197 (2): 229–35CrossRefGoogle Scholar
  15. 15.
    Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007 Sep; 22 (5): 299–308PubMedCrossRefGoogle Scholar
  16. 16.
    Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005 May; 162 (5): 1010–2PubMedCrossRefGoogle Scholar
  17. 17.
    Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010 Jul; 24 (7): 1011–8PubMedCrossRefGoogle Scholar
  18. 18.
    Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry 2010 Sep; 71 (9): 1243–4PubMedCrossRefGoogle Scholar
  19. 19.
    Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000 Nov 24; 68 (1): 29–39PubMedCrossRefGoogle Scholar
  20. 20.
    Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psych 2001 Mar; 158 (3): 360–9CrossRefGoogle Scholar
  21. 21.
    Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. Epub 2010 Aug 24Google Scholar
  22. 22.
    Boom S, Talluri K, Janssens L, et al. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009 Nov; 49 (11): 1318–30PubMedCrossRefGoogle Scholar
  23. 23.
    Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab and Dispos 2008 Apr; 36 (4): 769–79CrossRefGoogle Scholar
  24. 24.
    de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010 Jan–Feb; 51 (1): 80–8PubMedCrossRefGoogle Scholar
  25. 25.
    Canuso CM, Battisti WP. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. Expert Opin Pharmacother 2010 Oct; 11 (15): 2557–67PubMedCrossRefGoogle Scholar
  26. 26.
    Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009 Oct; 47 (10): 606–16PubMedGoogle Scholar
  27. 27.
    Tianmei S, Liang S, Yi L, et al. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. Human Psychopharm Clin 2010; 25: 404–9CrossRefGoogle Scholar
  28. 28.
    Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 2007 Apr; 32 (4): 757–64PubMedCrossRefGoogle Scholar
  29. 29.
    Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009 Jul; 42 (4): 158–63PubMedCrossRefGoogle Scholar
  30. 30.
    Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009 Oct; 24 (7): 532–9PubMedCrossRefGoogle Scholar
  31. 31.
    Malaspina D, Mark O, Gopal S, et al. Paternal age and treatment response in adolescents with schizophrenia [abstract 53]. Neuropsychopharmacology 2011 Dec; 36: S99Google Scholar
  32. 32.
    Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007 July; 93 (1–3): 117–30PubMedCrossRefGoogle Scholar
  33. 33.
    Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007 February; 90 (1–3): 147–61PubMedCrossRefGoogle Scholar
  34. 34.
    Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled Study. Biol Psychiatry 2007 15 Dec; 62 (12): 1363–70PubMedCrossRefGoogle Scholar
  35. 35.
    Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009 Jun; 166 (6): 691–701PubMedCrossRefGoogle Scholar
  36. 36.
    Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008 Jan; 16 (1): 31–43PubMedCrossRefGoogle Scholar
  37. 37.
    Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry 2009 Oct; 195 (4): 286–93PubMedCrossRefGoogle Scholar
  38. 38.
    Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008 May; 69 (5): 817–29PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations